LAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Standard BioTools Inc (LAB) is not a strong buy for a beginner investor with a long-term focus at this time. The technical indicators show a bearish trend with oversold conditions, but there is no clear signal for reversal. The company's financial performance has been weak, with significant revenue decline and negative net income. Additionally, there are no strong positive catalysts or trading signals to support a buy decision.
The MACD is negative and expanding downward (-0.0338), indicating bearish momentum. RSI is at 10.33, signaling oversold conditions. Moving averages are converging, suggesting indecision. Key support levels are at 1.14 and 1.056, with resistance at 1.278 and 1.415. The stock is trading below its pivot point, reflecting weakness.
The RSI indicates oversold conditions, which could lead to a potential bounce. The upcoming Q4 2025 earnings report on February 24, 2026, may provide clarity on the company's outlook.
Negative net income and declining gross margin. No significant insider or hedge fund activity. No recent congress trading data. The stock has a low probability of significant short-term gains (2.14% in the next month).
In Q3 2025, revenue dropped by 56.52% YoY to $19.55M. Net income improved but remained negative at -$34.69M (+28.77% YoY). EPS increased to -0.09 (+28.57% YoY). Gross margin fell to 48.51% (-6.22% YoY). Overall, the financials indicate poor growth trends.
No recent analyst rating or price target changes are available for LAB.
